Research Development

Staff Publications

 Small purple icon of a book with a magnifying glass on top  Staff Publications

Find out what your colleagues have been writing. This section features articles published by staff working for St Helens and Knowsley Teaching Hospitals and Halton, Knowsley and St Helens community staff.

Had something published and it's not included here? Let us know by completing this form.

Resources pertaining to writing for a publication and how to get published can be found by clicking here.

 

All publications by 'Hindle E'



Mersey and West Lancashire Teaching Hospitals NHS Trust – St Helens & Knowsley Staff

BI27: Two cases of capecitabine-induced subacute cutaneous lupus erythematosus

Abstract Capecitabine-induced subacute cutaneous lupus erythematosus is a documented but seemingly underappreciated phenomenon. We report our experience of two cases reviewed in a specialist immunochemotherapy dermatology clinic. A 73-year-old woman with a background of stage 4 oesophageal cancer presented with a rapidly progressive pruritic eruption. She had received one cycle of..

Published: 05/07/2022
Authors: Winters S, Hindle E

Read More

Cutaneous manifestations secondary to panitumumab therapy

  Lavery, MJ; Forsysth, L; Forsyth, L. (2021). Cutaneous manifestations secondary to panitumumab therapy. Clinics in Dermatology. epub 08 Aug  

Published: 08/08/2021
Authors: Lavery MJ, Hindle E

Read More

Beyond corticosteroids for the management of patients with cutaneous immune-related adverse events secondary to immune checkpoint inhibitors

Abstract Immune checkpoint inhibitors (ICIs) restore antitumour immunity and have revolutionized the treatment of several types of malignancy, including melanoma. However, these immunotherapeutic agents are often associated with immune‐related adverse events (irAEs), most commonly in the skin. Guidelines from the European Society for Medical Oncology recommend the use of..

Published: 01/09/2020
Authors: Hindle E

Read More

P097 Cutaneous toxicity from immune checkpoint inhibitors

Abstract Immune checkpoint inhibitors (ICIs) are immunomodulatory agents used in the treatment of an increasing number of malignancies. They inhibit tumour-induced immunosuppression and reactivate tumour-specific cytotoxic T lymphocytes resulting in control of malignant disease (Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64). However, off-target..

Published: 23/12/2019
Authors: Hindle E

Read More

Squamous cell carcinoma and vitiligo

​ Ultraviolet radiation predisposes to the development of nonmelanoma skin cancer (NMSC). Melanin safeguards the skin against this. This leads one to conjecture that patients with vitiligo are at a higher risk of developing skin malignancies. However, despite the lack of protective melanin and increased oxidative stress due to epidermal hydrogen..

Published: 19/07/2016
Authors: Hindle E

Read More

St Helens Community Staff

No results for this category.

Knowsley Community Staff

No results for this category.

Halton Community Staff

No results for this category.

North West Boroughs Community Health Staff

No results for this category.